Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2025-10-07 Regulatory Filings
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
Regulatory Filings Classification · 95% confidence The document is a press release issued by Inventiva announcing that they will present four abstracts at the upcoming AASLD The Liver Meeting 2025. It provides details on the presentation titles, authors, and dates, and includes standard corporate boilerplate information about the company and its lead product candidate, lanifibranor. It does not contain the actual financial results, audit reports, or proxy materials, but rather serves as a general regulatory announcement regarding company activities. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-10-07 English
Inventiva annonce la nomination d’Andrew Obenshain au poste de Directeur Général
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new CEO (Andrew Obenshain) at Inventiva. It details the leadership transition, provides background on the new CEO, and includes standard corporate boilerplate and forward-looking statements. This falls under the category of management changes and board-related announcements.
2025-10-01 French
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Chief Executive Officer (Andrew Obenshain) and the departure of the former CEO (Frédéric Cren). It details the leadership transition, provides biographical information on the new CEO, and includes standard corporate boilerplate and forward-looking statement disclaimers. This falls squarely under the category of board and management changes.
2025-10-01 English
Inventiva publie ses résultats financiers non audités du premier semestre 2025 et fait le point sur ses activités
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2025 (H1 2025) for Inventiva. It includes detailed financial statements (income statement, cash flow analysis), management's discussion and analysis of financial results, and updates on business activities and R&D. It is not a short announcement (over 30,000 characters) and contains substantive financial data, qualifying it as an Interim/Quarterly Report (IR) rather than a simple press release or announcement. H1 2025
2025-09-29 French
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the six-month period ended June 30, 2025. It includes detailed financial statements (income statement, cash flow analysis), management's discussion and analysis of financial results, and corporate updates. It is not a short announcement or a press release, but rather a substantive interim financial report containing actual financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-09-29 English
RFS
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL' (Half-Year Financial Report) for the period ending June 30, 2025. It contains a detailed summary, management discussion and analysis (Rapport semestriel d'activité), and condensed consolidated financial statements (Etats financiers semestriels). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2025
2025-09-29 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.